Eleven genetically confirmed FRDA patients (age range 6.9–17.8; mean±SD 13.4±3 years; 8 females) were enrolled in this study. Patients were age-matched with 13 typically developing children and adolescents (age range 5.5–14;mean±SD10.3±3; 7females). Table 1 shows the clinical and functional characteristics of our cohort. Nine participants were able to walk independently, 2 patients needed mild walking aids (cans). All the patients were taking idebenone (10 mg/kg/day) for more than 6 months at the time of the study[23–26]. All the patients were able to complete the entire protocol in an outpatient setting. No patient had visual impairment except for slight abnormalities of eye movements (fixation instability, square wave jerks).